Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

Returns on capital

Insight Molecular Diagnostics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

159.6%

avg -93.0%

ROIC

-197.4%

avg -121.5%

ROA

-195.0%

avg -102.6%

Analysis

ROE is currently the strongest return metric at 159.6% versus its period average of -93.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joshua Riggs

President, Chief Executive Officer & DirectorUSD 662.79K43——

Ekkehard Schutz

Chief Science OfficerUSD 552.01K———

Andrea Susan James

Chief Financial OfficerUSD 536.58K44——

James Liu

Vice President of Accounting, Treasurer, Controller & Principal Accounting OfficerUSD 303.25K30——

Michael D. West

Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.—7360.00K0.22%

Paul R. Billings FACP

Consulting Chief Medical Officer—74——

Peter Hong

Vice President, General Counsel & Secretary————

Steven Tahmooressi

Vice President of Marketing————

Yuh-Min Chiang

Chief Technology Officer————

Sandra O'Donald

Senior Vice President of Business Operations————

Donnie Purto

SVP of Sales & Sales Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 16, 2016.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

14

$5.69M

Sells

0

$0.00

Net Transaction Value

+$5.69M

Net buying

Most Active

BROADWOOD PARTNERS, L.P.

14 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 27, 26

BROADWOOD PARTNERS, L.P.

Indirect

Buy$0
Apr 27, 26

BROADWOOD PARTNERS, L.P.

Direct

Buy$913.1K
Apr 24, 26

BROADWOOD PARTNERS, L.P.

Indirect

Buy$0
Apr 24, 26

BROADWOOD PARTNERS, L.P.

Direct

Buy$137.1K
Apr 23, 26

BROADWOOD PARTNERS, L.P.

Indirect

Buy$0
Apr 23, 26

BROADWOOD PARTNERS, L.P.

Direct

Buy$982K
Apr 20, 26

BROADWOOD PARTNERS, L.P.

Indirect

Buy$0
Apr 20, 26

BROADWOOD PARTNERS, L.P.

Direct

Buy$158K
Apr 17, 26

BROADWOOD PARTNERS, L.P.

Indirect

Buy$0
Apr 17, 26

BROADWOOD PARTNERS, L.P.

Direct

Buy$143.3K

1–10 of 14

Summary

Insiders reported 14 buys worth $5.69M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.69M. BROADWOOD PARTNERS, L.P. was the most active insider with 14 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A+61.8%
+75.7% (3yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +61.8% over three years. Forward estimates point to Revenue at +75.7% (3yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Insight Molecular Diagnostics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IMDX's management, answered from reported figures.

Who manages IMDX?

Insight Molecular Diagnostics Inc. (IMDX) lists 11 active executives. The top listed executive is Ekkehard Schutz, Chief Science Officer.

Are IMDX insiders buying or selling?

Recent insider activity shows net buying of $60.61M.